16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Book Chapter: not found
      Dermatological and Transdermal Formulations 

      Bioavailability and Bioequivalence of Dermatological Formulations

      monograph
      ,
      CRC Press

      Read this book at

      Buy book Bookmark
          There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references354

          • Record: found
          • Abstract: found
          • Article: not found

          A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

          The statistical test of hypothesis of no difference between the average bioavailabilities of two drug formulations, usually supplemented by an assessment of what the power of the statistical test would have been if the true averages had been inequivalent, continues to be used in the statistical analysis of bioavailability/bioequivalence studies. In the present article, this Power Approach (which in practice usually consists of testing the hypothesis of no difference at level 0.05 and requiring an estimated power of 0.80) is compared to another statistical approach, the Two One-Sided Tests Procedure, which leads to the same conclusion as the approach proposed by Westlake based on the usual (shortest) 1-2 alpha confidence interval for the true average difference. It is found that for the specific choice of alpha = 0.05 as the nominal level of the one-sided tests, the two one-sided tests procedure has uniformly superior properties to the power approach in most cases. The only cases where the power approach has superior properties when the true averages are equivalent correspond to cases where the chance of concluding equivalence with the power approach when the true averages are not equivalent exceeds 0.05. With appropriate choice of the nominal level of significance of the one-sided tests, the two one-sided tests procedure always has uniformly superior properties to the power approach. The two one-sided tests procedure is compared to the procedure proposed by Hauck and Anderson.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Severe Psoriasis – Oral Therapy with a New Retinoid

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              “Proving the null hypothesis” in clinical trials

              When designing a clinical trial to show whether a new or experimental therapy is as effective as a standard therapy (but not necessarily more effective), the usual null hypothesis of equality is inappropriate and leads to logical difficulties. Since therapies cannot be shown to be literally equivalent, the appropriate null hypothesis is that the standard therapy is more effective than the experimental therapy by at least some specified amount. The problem is presented in terms of a trial in which the outcome of interest is dichotomous; test statistics, confidence intervals, and sample size calculations are discussed. The required sample size may be larger for either null hypothesis formulation than for the other, depending on the specific assumptions made. Reporting results in terms of confidence intervals is especially useful for this type of trial.
                Bookmark

                Author and book information

                Book Chapter
                February 20 2002
                December 17 2009
                : 396-493
                10.1201/9780824743239.ch8
                ebea76ac-c921-49a5-9d51-60de5fbcfc48
                History

                Comments

                Comment on this book

                Book chapters

                Similar content1,856

                Cited by2